Tobira Therapeutics, Inc. Common Stock
TBRA
TBRA was delisted on the 31st of October, 2016.
15 hedge funds and large institutions have $10.9M invested in Tobira Therapeutics, Inc. Common Stock in 2013 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 15 → 15 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
29% less capital invested
Capital invested by funds: $15.4M → $10.9M (-$4.47M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$261K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$110K |
| 3 |
Goldman Sachs
New York
|
+$105K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$58.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$11.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$234K |
| 2 |
WC
Wexford Capital
West Palm Beach,
Florida
|
-$168K |
| 3 |
Jane Street
New York
|
-$98K |
| 4 |
SIM
Spark Investment Management
New York
|
-$65.2K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$50.1K |
TBRA Hedge Fund Activity: Q4 2013 in Review
15 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Tobira Therapeutics, Inc. Common Stock (TBRA) for Q4 2013, worth a combined $10.9M — down 29% from $15.4M a quarter earlier.
Fund positioning in TBRA was balanced in Q4 2013: 2 funds opened new positions, 2 closed out, 5 added to existing stakes and 5 trimmed.
The largest buyer was Alyeska Investment Group, adding an estimated $261K. The largest seller was Morgan Stanley, cutting an estimated $234K.
- 15 institutional investors held Tobira Therapeutics, Inc. Common Stock (TBRA) as of Q4 2013, unchanged from Q3 2013.
- Funds reported $10.9M of Tobira Therapeutics, Inc. Common Stock stock for Q4 2013, down 29% quarter-over-quarter.
- 2 funds opened new Tobira Therapeutics, Inc. Common Stock positions in Q4 2013 and 2 closed out, a net change of 0 holders.
- The largest Tobira Therapeutics, Inc. Common Stock buyer in Q4 2013 was Alyeska Investment Group, an estimated $261K added.
- The largest Tobira Therapeutics, Inc. Common Stock seller in Q4 2013 was Morgan Stanley, an estimated $234K sold.
Based on aggregated 13F filings for Q4 2013.